Upon multivariate analysis , non-HER2-gene gains independently predicted for shorter disease-free survival ( DFS ) and overall survival ( OS ) in patients with triple-negative cancer , as compared to luminal and HER2-positive tumors ( interaction p = 0.007 for DFS and p = 0.011 for OS ) .